Drug-induced agranulocytosis is a severe complication that has been implicated with most classes of medications. Medications such as clozapine, trimethoprim-sulfamethoxazole and methimazole have been more commonly associated with agranulocytosis than other agents. Although the pathogenesis isn't fully elucidated, it appears to be two-fold with a direct toxicity to the myeloid cell line and immune-mediated destruction. Patients may be asymptomatic at the time neutropenia is discovered or may present with more severe complications such as sepsis. In approximately 5% of cases drug-induced agranulocytosis may be fatal. Management of drug-induced agranulocytosis includes the immediate discontinuation of the offending medication, initiation of broad-spectrum antibiotics and consideration of the use of granulocyte colony-stimulating factors in high-risk patients.
AndresEFedericiLWeittenT. Recognition and management of drug-induced blood cytopenias: the example of drug-induced acute neutropenia and agranulocytosis. Expert Opin Drug Saf. 2008;7(4):481–489.
5.
TesfaDKeisuMPalmbladJ. Idiosyncratic drug-induced agranulocytosis: Possible mechanisms and management. Am J Hematol. 2009;84(7):428–434.
6.
BhattVSaleemA. Review: drug-induced neutropenia—pathophysiology, clinical features, and management. Ann Clin Lab Sci. 2004:32(2):131–137.
7.
AndresEKurtzJEMaloiselF. Nonchemotherapy drug-induced agranulocytosis: experience of the Stasbourg teaching hospital (1985-2000) and review of the literature. Clin Lab Haem. 2002;24(2):99–106.
AndresEMaloiselFZimmerJ. The role of haematopoietic growth factors granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in the management of drug-induced agranulocytosis. Br J Haematol. 2010;150(1):3–8.
10.
MaloiselFAndresEKaltenbachG. Prognostic factors of hematologic recovery in nonchemotherapy drug-induced agranulocytosis. Haematologica. 2003;88(4):470–471.
11.
AndresEKurtzJEPerrinAE. Haematopoietic growth factor in antithryoid-drug-induced agranulocytosis. QJM. 2001;94(8):423–428.
12.
FukataSKumaKSugawaraM. Granulocyte colony-stimulating factor (G-CSF) does not improve recovery from antithyroid drug-induced agranulocytosis: a prospective study. Thyroid. 1999;9(1):29–31.
13.
BerlinerNHorwitzMLoughranTPJr. Congenital and acquired neutropenia. Hematology. 2004;63–79.
14.
AndresEMaloiselF. Antibiotic-induced agranulocytosis: a monocentric study of 21 cases. Arch Intern Med. 2001;161(21):2619.
15.
AndresEMalosielFKurtzJE. Modern management of non-chemotherapy drug-induced agranulocytosis: a monocentric cohort study of 90 cases and review of the literature. Eur J Intern Med. 2002;13(5):324–328.
16.
OlaisonLBelinLHogevikH. Incidence of B-lactam-induced delayed hypersensitivity and neutropenia during treatment of infective endocarditis. Arch Intern Med. 1999;159(6):607–615.
17.
Segarra-NewnhamMTagoffSS. Probable vancomycin induced neutropenia. Ann Pharmacother. 2004;38(11):1855–1859.
18.
BlackELauTTYEnsomMHH. Vancomycin-induced neutropenia: Is it dose- or duration-related?Ann Pharmacother. 2011;45(5):629–638.
19.
FlanaganRJDunkL. Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol Clin Exp. 2008;23(suppl 1):27–41.
20.
NielsenJCorrellCManuP. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?J Clin Psychiatry. 2013;74(6):603–613.
21.
NooijenPMMCarvalhoFFlanaganRJ. Haematological toxicity of clozapine and some other drugs used in psychiatry. Hum Psychopharmacol Clin Exp. 2011;26(2):112–119.
EspositoDAouilleJRouillonF. Two year follow-up of a patient with successful continuation of clozapine treatment despite morning pseudoneutropenia. J Clin Psychiatry. 2006;65(9):1281.
25.
MattaiAFungLBakalarJ. Adjunctive use of lithium carbonate for the management of neutropenia in clozapine-treated children. Hum Psychopharmacol Clin Exp. 2009;24(7):584–589.
26.
KutscherECRobbinsGPKennedyWK. Clozapine-induced neutropenia successfully treated with lithium. Am J Health Syst Pharm. 2007;64(19):2027–2031.
27.
AndresEZimmerJAffenbergerS. Idiosyncratic drug-induced agranulocytosis: update of an old disorder. Eur J Intern Med. 2006;17(8):529–535.
28.
TakataKKubotaSFukataS. Methimazole-induced agranulocytosis in patients with Graves’ disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid. 2009;19(6):559–563.
29.
HuangCHLiKLWuJH. Antithyroid drug-induced agranulocytosis: report of 13 cases. Chang Gung Med J. 2007;30(3):242–248.
30.
CooperDS. Antithyroid drugs. N Engl J Med. 2005;352(9):905–917.
31.
TamaiHSudoTKimuarA. Association between the DRB1*08032 histocompatibility antigen and methimazole-induced agranulocytosis in Japanese patients with Graves disease. Ann Intern Med. 1996;124(5):490–494.
